

# The Medical Letter<sup>®</sup>

## on Drugs and Therapeutics

Volume 65

November 13, 2023

ISSUE No.  
**1689**

### IN THIS ISSUE

In Brief: Empagliflozin (*Jardiance*) for Chronic Kidney Disease .....p 183

## Important Copyright Message

### FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)  
or call customer service at: 800-211-2769

# The Medical Letter®

## on Drugs and Therapeutics

Volume 65 (Issue 1689)

November 13, 2023

Take CME Exams

### IN BRIEF

## Empagliflozin (*Jardiance*) for Chronic Kidney Disease

The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (*Jardiance* – Boehringer Ingelheim/Lilly) is now FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease (CKD) at risk of progression. It is also approved to improve glycemic control in patients  $\geq 10$  years old with type 2 diabetes, to reduce the risk of cardiovascular death and hospitalization for heart failure (HF) in adults with HF, and to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

**OTHER SGLT2 INHIBITORS** – The SGLT2 inhibitors canagliflozin (*Invokana*) and dapagliflozin (*Farxiga*) are also approved to improve renal outcomes (see Table 1). The SGLT2 inhibitors ertugliflozin (*Steglatro*) and bexagliflozin (*Brenzavvy*) and the SGLT1/2 inhibitor sotagliflozin (*Inpefa*) have not been approved by the FDA for any renal indications.<sup>1-3</sup>

**Table 1. Renal Indications for SGLT2 Inhibitors**

Canagliflozin ( <i>Invokana</i> )
▶ To reduce the risk of end-stage kidney disease, doubling of serum creatinine, CV death, and hospitalization for HF in adults with type 2 diabetes and diabetic nephropathy with albuminuria
Dapagliflozin ( <i>Farxiga</i> )
▶ To reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization for HF in adults with CKD at risk of progression
Empagliflozin ( <i>Jardiance</i> )
▶ To reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, and hospitalization in adults with CKD at risk of progression

CKD = chronic kidney disease; CV = cardiovascular; HF = heart failure

**CLINICAL STUDIES** – Approval of the new indication for empagliflozin was based on the results of a double-blind trial (EMPA-KIDNEY) in 6609 patients (with or without type 2 diabetes) with CKD (eGFR  $\geq 20$ - $<45$  mL/min/1.73 m<sup>2</sup>, or eGFR  $\geq 45$ - $<90$  mL/min/1.73 m<sup>2</sup> with a urine albumin-to-creatinine

**Table 2. EMPA-KIDNEY Clinical Trial Results<sup>1</sup>**

Endpoint	Empagliflozin (n=3304)	Placebo (n=3305)
Progression of kidney disease or CV death <sup>2</sup>	13.1%*	16.9%
Hospitalization for HF or CV death	4.0%	4.6%
All-cause hospitalization <sup>3</sup>	24.8 events/100 patient-years*	29.2 events/100 patient-years
All-cause mortality	4.5%	5.1%
Progression of kidney disease	11.6%	15.2%
CV death	1.8%	2.1%
End-stage kidney disease or CV death	4.9%	6.6%

\*Statistically significant difference vs placebo; CV = cardiovascular; HF = heart failure

1. Includes patients with or without type 2 diabetes. About 86% of patients were taking a renin-angiotensin system inhibitor. The EMPA-KIDNEY Collaborative Group. *N Engl J Med* 2023; 388:117.

2. The primary endpoint. Progression of kidney disease was defined as end-stage kidney disease, a sustained decrease in eGFR to  $<10$  mL/min/1.73 m<sup>2</sup>, a sustained decrease in eGFR of  $\geq 40\%$  from baseline, or death from renal causes.

3. Hospitalizations included first and all subsequent events.

ratio  $\geq 200$  mg/g). Patients were randomized to receive empagliflozin 10 mg or placebo once daily in addition to a renin-angiotensin system inhibitor. Over a median follow-up of 2 years, the incidence of the primary endpoint, a composite of progression

**Table 3. Dosage and Cost of SGLT2 Inhibitors with Renal Indications**

Drug	Usual Adult Dosage <sup>1</sup>	Cost <sup>2</sup>
Canagliflozin – <i>Invokana</i> (Janssen)	100 mg PO once/day <sup>3</sup>	\$598.60 <sup>4</sup>
Dapagliflozin – <i>Farxiga</i> (AstraZeneca)	10 mg PO once/day <sup>5</sup>	565.30
Empagliflozin – <i>Jardiance</i> (Boehringer Ingelheim/Lilly)	10 mg PO once/day	593.30

1. Dosage for renal indication. Higher doses may be needed for glycemic control. SGLT2 inhibitors should be taken in the morning to avoid nocturia. Dapagliflozin and empagliflozin can be taken with or without food; canagliflozin should be taken before the first meal of the day.

2. Approximate WAC for 30 days' treatment. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. October 5, 2023. Reprinted with permission by First Databank, Inc. All rights reserved. ©2023. www.fdbhealth.com/drug-pricing-policy.

3. Initiation is not recommended in patients with an eGFR  $<30$  mL/min/1.73 m<sup>2</sup>. Patients with albuminuria  $>300$  mg/day may continue taking 100 mg/day to reduce the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure.

4. The cost of a 30-day supply, excluding shipping and handling, from Mark Cuban Cost Plus Drug Company (www.costplusdrugs.com) is \$245.92. Accessed October 26, 2023.

5. Initiation is not recommended in patients with an eGFR  $<25$  mL/min/1.73 m<sup>2</sup>.

of kidney disease or cardiovascular death, was statistically significantly lower with empagliflozin than with placebo. The rate of hospitalization for any cause was also statistically significantly lower with empagliflozin than with placebo, but the rates of all-cause mortality and a composite of hospitalization for heart failure or cardiovascular death were not (see Table 2).<sup>4</sup>

No trials directly comparing the renal benefits of empagliflozin with those of canagliflozin or dapagliflozin are available.

**ADVERSE EFFECTS** – SGLT2 inhibitors, including empagliflozin, can increase the risk of genital mycotic infection, urinary tract infection, volume depletion, hypotension, and ketoacidosis in

patients with type 2 diabetes. In EMPA-KIDNEY, lower limb amputations occurred in 28 patients in the empagliflozin group and in 19 of those in the placebo group.

**DOSAGE, ADMINISTRATION, AND COST** – The recommended dosage of empagliflozin for all indications is 10 mg taken once daily in the morning. The dose can be increased to 25 mg in patients who need additional glycemic control. ■

1. Drugs for type 2 diabetes. *Med Lett Drugs Ther* 2022; 64:177.
2. Bexagliflozin (Brenzavvy) – a fifth SGLT2 inhibitor for type 2 diabetes. *Med Lett Drugs Ther* 2023; 65:130.
3. Sotagliflozin (Inpefa) for heart failure. *Med Lett Drugs Ther* 2023; 65:114.
4. The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. *N Engl J Med* 2023; 388:117.

**PRESIDENT:** Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

**CONTRIBUTING EDITORS:** Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

**MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS:** Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

**FULFILLMENT AND SYSTEMS MANAGER:** Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli  
**EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS:** Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

**Copyright and Disclaimer:** The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

#### Subscription Services

#### Address:

The Medical Letter, Inc.  
145 Huguenot St. Ste. 312  
New Rochelle, NY 10801-7537  
www.medicalletter.org

#### Customer Service:

Call: 800-211-2769 or 914-235-0500  
Fax: 914-632-1733  
E-mail: custserv@medicalletter.org

#### Permissions:

To reproduce any portion of this issue,  
please e-mail your request to:  
permissions@medicalletter.org

#### Subscriptions (US):

1 year - \$159; 2 years - \$298;  
3 years - \$398. \$65 per year  
for students, interns, residents,  
and fellows in the US and Canada.  
Reprints - \$45 per issue or article

#### Site License Inquiries:

E-mail: SubQuote@medicalletter.org  
Call: 800-211-2769  
Special rates available for bulk  
subscriptions.